Miho Fukui

Miho Fukui, MD, PhD

Associate Scientific Director, Imaging Core Lab

Dr. Miho Fukui started at the Minneapolis Heart Institute Foundation as a Senior International Research Scholar at the Valve Science Center. She completed her cardiology training in Hyogo, Japan. In October 2017, she came to University of Pittsburgh as a post-doctorate research scholar to obtain advanced training in multi-modality imaging in structure/valvular heart disease under the supervision of Dr. João Cavalcante. In September 2018, she started at the Valve Science Center at Minneapolis Heart Institute Foundation and is now the lead analyst for the Cardiovascular Imaging Research Center. In her career, she has co-authored over 45 peer-reviewed publications, including a first author role on many of them. Miho has also given 36 scientific presentations and was recognized as a “Young Leader” at the Cardiovascular Research Technologies (CRT) conference in 2022. 

Back to Imaging Team

Miho Fukui
Give the Gift of Hope
4 photos of families smiling

The Minneapolis Heart Institute Foundation® (MHIF) strives to create a world without heart and vascular disease. To achieve this bold vision, we are dedicated to improving the cardiovascular health of individuals and communities through innovative research and education.

Thanks to the generosity of donors like you, we can continue this life-saving work. Please make a gift to support the area of greatest need.

Research Milestone: FDA approves device used as alternative to open-heart

blue background
Triclip team

We are honored to celebrate the culmination of years of research that has resulted in new technologies for patients! In the few last weeks, we announced a similar research milestone with the FDA approval of the TriClip system for tricuspid regurgitation. We celebrated this important milestone with local media KSTP-TV, who spotlighted the importance of this new technology. We were proud to be a leading clinical site led by Global PI Dr. Paul Sorajja and the MHIF research team who contributed significant data to the pivotal trial.